Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2017 Jan 13;12(1):e0169024.
doi: 10.1371/journal.pone.0169024. eCollection 2017.

Medium Cut-Off (MCO) Membranes Reduce Inflammation in Chronic Dialysis Patients-A Randomized Controlled Clinical Trial

Daniel Zickler  1 , Ralf Schindler  1 , Kevin Willy  1 , Peter Martus  2 , Michael Pawlak  3 , Markus Storr  4 , Michael Hulko  4 , Torsten Boehler  4 , Marcus A Glomb  5 , Kristin Liehr  5 , Christian Henning  5 , Markus Templin  3 , Bogusz Trojanowicz  6 , Christof Ulrich  6 , Kristin Werner  4 , Roman Fiedler  6 , Matthias Girndt  6
Affiliations
Randomized Controlled Trial

Medium Cut-Off (MCO) Membranes Reduce Inflammation in Chronic Dialysis Patients-A Randomized Controlled Clinical Trial

Daniel Zickler et al. PLoS One. .

Abstract

Background: To increase the removal of middle-sized uremic toxins a new membrane with enhanced permeability and selectivity, called Medium Cut-Off membrane (MCO-Ci) has been developed that at the same time ensures the retention of albumin. Because many middle-sized substances may contribute to micro-inflammation we hypothesized that the use of MCO-Ci influences the inflammatory state in hemodialysis patients.

Methods: The randomized crossover trial in 48 patients compared MCO-Ci dialysis to High-flux dialysis of 4 weeks duration each plus 8 weeks extension phase. Primary endpoint was the gene expression of TNF-α and IL-6 in peripheral blood mononuclear cells (PBMCs), secondary endpoints were plasma levels of specified inflammatory mediators and cytokines.

Results: After four weeks of MCO-Ci the expression of TNF-α mRNA (Relative quantification (RQ) from 0.92 ± 0.34 to 0.75 ± 0.31, -18.5%, p<0.001)-α and IL-6 mRNA (RQ from 0.78 ± 0.80 to 0.60 ± 0.43, -23.1%, p<0.01) was reduced to a significantly greater extent than with High-flux dialyzers (TNF mRNA-RQ: -14.3%; IL-6 mRNA-RQ: -3.5%). After retransformation of logarithmically transformed data, measurements after MCO were reduced to 82% of those after HF (95% CI 74%-91%). 4 weeks use of MCO-Ci resulted in long-lasting change in plasma levels of several cytokines and other substances with a significant decrease for sTNFR1, kappa and lambda free light chains, urea and an increase for Lp-PLA2 (PLA2G7) compared to High-flux. Albumin levels dropped significantly after 4 weeks of MCO dialysis but increased after additional 8 weeks of MCO dialysis. Twelve weeks treatment with MCO-Ci was well tolerated regarding the number of (S)AEs. In the extension period levels of CRP, TNF-α-mRNA and IL-6 mRNA remained stable in High-flux as well as in MCO-Ci.

Conclusions: MCO-Ci dialyzers modulate inflammation in chronic HD patients to a greater extent compared to High-flux dialyzers. Transcription of pro-inflammatory cytokines in peripheral leukocytes is markedly reduced and removal of soluble mediators is enhanced with MCO dialysis. Serum albumin concentrations stabilize after an initial drop. These results encourage further trials with longer treatment periods and clinical endpoints.

PubMed Disclaimer

Conflict of interest statement

We have the following interests: Markus Storr, Torsten Boehler, Michael Hulko, and Kristin Werner are employees of Gambro Dialysatoren GmbH, Research & Development, Hechingen, Germany. Gambro AB (including all direct and indirect subsidiaries) is part of Baxter International Inc. Markus Pawlak and Michael Templin are employees of the NMI Technology Transfer GmbH. Financial support for this study comes in part from Gambro Dialysatoren GmbH, Hechingen. (http://www.gambro.de/). There are no patents, products in development or marketed products to declare. This does not alter our adherence to all the PLOS ONE policies on sharing data and materials.

Figures

Fig 1
Fig 1. Patient Flow Chart.
Fig 2
Fig 2. Expression of TNF-mRNA and IL-6-mRNA (log scale of arbitrary units) before and after the cross-over periods using High-flux or MCO dialyzers.
Each dot (MCO: solid; Highflux: open) represents a single patient. Note that the regression line of the MCO phase is lower and does not cross the line of the High-flux period; the difference between High-flux and MCO is significant, p<0.01.
See this image and copyright information in PMC

References

    1. Duranton F, Cohen G, De Smet R, Rodriguez M, Jankowski J, Vanholder R, et al. Normal and pathologic concentrations of uremic toxins. J Am Soc Nephrol. 2012;23(7):1258–70. PubMed Central PMCID: PMC3380651. 10.1681/ASN.2011121175 - DOI - PMC - PubMed
    1. Vanholder R, De Smet R, Glorieux G, Argiles A, Baurmeister U, Brunet P, et al. Review on uremic toxins: classification, concentration, and interindividual variability. Kidney international. 2003;63(5):1934–43. 10.1046/j.1523-1755.2003.00924.x - DOI - PubMed
    1. Liabeuf S, Lenglet A, Desjardins L, Neirynck N, Glorieux G, Lemke HD, et al. Plasma beta-2 microglobulin is associated with cardiovascular disease in uremic patients. Kidney international. 2012;82(12):1297–303. 10.1038/ki.2012.301 - DOI - PubMed
    1. Eknoyan G, Beck GJ, Cheung AK, Daugirdas JT, Greene T, Kusek JW, et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis. The New England journal of medicine. 2002;347(25):2010–9. 10.1056/NEJMoa021583 - DOI - PubMed
    1. Locatelli F, Martin-Malo A, Hannedouche T, Loureiro A, Papadimitriou M, Wizemann V, et al. Effect of membrane permeability on survival of hemodialysis patients. Journal of the American Society of Nephrology: JASN. 2009;20(3):645–54. PubMed Central PMCID: PMC2653681. 10.1681/ASN.2008060590 - DOI - PMC - PubMed

Publication types